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Edited by Robert BaroukiAbstract CYP4A11, the major fatty acid x-hydroxylase in hu-
man liver is involved in the balance of lipids, but its role and reg-
ulation are both poorly understood. We studied the eﬀects of
retinoids on the regulation of CYP4A11 in the human hepatoma
cell line HepaRG. Treatment of HepaRG cells with all-trans-ret-
inoic acid resulted in a strong decrease in CYP4A11 gene expres-
sion and apoprotein content and, furthermore, was associated
with a 50% decrease in the microsomal lauric acid hydroxylation
activity. Such a strong suppression of CYP4A11 expression by
retinoids could have a major impact on fatty acid metabolism
in the liver.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Among the human cytochromes P450 (CYP), the fatty acid
x-hydroxylase CYP4A sub-family is involved in the metabo-
lism of medium- and long-chain fatty acids. The bioactivation
of fatty acids to x-hydroxymetabolites are believed to play an
important role in the regulation of kidney function and sys-
temic blood pressure [1]. CYP4A11 is the main fatty acid x-
hydroxylating enzyme expressed in human liver and kidney
[2–4]. In the rat, the expression of CYP4A1, the major fatty
acid hydroxylase of the liver, is regulated by physiological con-
ditions including diabetes and fasting [5–7] and can be induced
by diﬀerent compounds, e.g., fatty acids and peroxisome pro-
liferators like hypolipidemic drugs [8]. These eﬀects are consid-Abbreviations: ATRA, all-trans-retinoic acid; Bezaf, bezaﬁbrate; 9-cis-
RA, 9-cis-retinoic acid; CYP, cytochrome P450; FAS, fatty acid syn-
thase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; x-LAH,
lauric acid x-hydroxylase; LTB4, leukotriene B4; PGJ2, 15-deoxypro-
staglandine J2; PPAR, peroxisome proliferator-activated receptor;
2BrP, 2-bromopalmitate; RAR, retinoic acid receptor; RARE,
retinoic acid response element; RXR, retinoid X receptor
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doi:10.1016/j.febslet.2006.05.006ered to be mediated via the peroxisome proliferator-activated
receptor alpha (PPARa) [6].
Because of the lack of appropriate cell systems, the regula-
tion of human CYP4A gene expression is poorly documented.
In HepG2 hepatoma cells in which was overexpressed a murine
PPARa mutant exhibiting a signiﬁcantly decreased ligand-
independent trans-activation potential, CYP4A11 is induced
by peroxisome proliferators [9]. In primary cultures of human
hepatocytes, the PPARa agonist, cloﬁbrate, increases
CYP4A11 mRNA [10].
CYP4A members exhibit a marked physiological role in the
maintenance of lipid homeostasis in rodents, especially as
PPARa responsive genes, but the existence of such a mecha-
nism in humans is still debated.
The lipid-soluble vitamin A and its derivatives, all-trans-ret-
inoic acid (ATRA) and 9-cis-retinoic acid (9-cis-RA), exert
various eﬀects on lipid metabolism by interrupting lipid perox-
idation chain reaction (neutralising singlet oxygen) and regu-
lating enzymes involved in the metabolism of triglycerides
[11,12], cholesterol [12,13] and fatty acids [14,15]. In rats, sup-
plementation with b-carotene induces several CYP genes
including CYP1A1/2, CYP3A1/2, CYP2E1, CYP2B1/2 and
CYP2C11 in the liver [16].
Retinoids are natural and synthetic derivatives of retinol,
and among them ATRA and its stereoisomer, 9-cis-RA, are
biologically active. By their ability to modulate cell prolifera-
tion, diﬀerentiation and apoptosis, depending on the cell phe-
notype, they both control carcinogenesis. Retinoids act as
chemopreventive agents in rats over the initial phase of
hepatocarcinogenesis [17,18], but induce hepatic cell prolifera-
tion in normal mice [19]. In the human hepatoma cell line
HepG2, retinoic acid induces growth arrest and diﬀerentiation
[20]. The survival rate of patients with hepatocarcinoma was
signiﬁcantly prolonged by a 12-months postoperative treat-
ment with retinoids as adjuvant treatment [21].
Retinoids exert their eﬀects activities through interactions
with the retinoic acid receptor (RAR) and retinoid X receptor
(RXR) nuclear receptors found as three isotypes (a, b and c).
These ligand-activated receptors act as transcription factors
and lead to transcriptional stimulation or repression by bind-
ing to RA response elements in the control region of numerous
target genes. Moreover, both are essential in the regulation of
gene transcription by retinoids. RXR also plays a unique role
in the nuclear receptor family as a common heterodimeric
partner for several other nuclear receptors during transcriptionblished by Elsevier B.V. All rights reserved.
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assessing whether retinoids can regulate the CYP4A11 fatty
acid hydroxylase in human hepatoma cells. The HepaRG cell
line being the ﬁrst human hepatoma cell line to stably express
high levels of the main CYPs involved in xenobiotic metabo-
lism [22], it appeared to be a relevant in vitro model; it also ex-
presses genes implicated in lipid metabolism, including
PPARa, SREBP1c, fatty acid synthase (FAS), CYP3A4 and
CYP4F3 at levels close to those found in liver biopsies [23]
(and unpublished data). In the present study, we provide evi-
dence for a strong downregulation by ATRA of CYP4A11
gene expression, protein and associated catalytic activities.2. Materials and methods
2.1. Chemicals
Retinoic acids, L165,041, bezaﬁbrate (Bezaf) were from Sigma
(Saint Quentin Fallavier, France). Lauric acid was obtained from Flu-
ka (Buchs, Switzerland). Radiolabeled [1-14C]-lauric acid (1.85 GBq/
mmol) was from Amersham Biotech (Amersham, UK). Culture media
and glutamine were purchased from Gibco BRL (Cergy-Pontoise,
France), sera from Perbio (France), insulin from Sigma and hydrocor-
tisone hemisuccinate from Upjohn Pharmacia (Guyancourt, France).
Electrophoresis reagents were from Bio-Rad (France), nitrocellulose
sheets from Amersham Biotech and immunoblot primary antibodies
from RDI (Research Diagnostics Incorporation, Flanders, NJ). Mod-
iﬁed cell microsomes containing human P450s were obtained from
Gentest (Woburn, MA). All other chemicals and solvents were of ana-
lytical grade from Sigma or VWR International (Pessac, Fance).
2.2. Cell culture
Hepa RG cells were seeded in six-well plates in 2 mL of complete
medium composed of William’s E media supplemented with 5 U/mL
penicillin, 5 lg/mL streptomycin, 10% fetal calf serum (HYCLONE:
Fetalclone III Bovine serum product), 200 mM L-glutamine, 5 lg/mL
insulin and 5 · 105 M hydrocortisone. After 12 days, the medium
was supplemented at ﬁrst with 1% DMSO and then with 2% DMSO
till the 24th day, when the diﬀerent treatments were applied.
2.3. RNA extraction and detection of RNA damage
Total RNA was extracted using the ABI Prisme 6100 Nucleic Acid
PrepStation (Applied Biosystems, France). The cells were washed with
PBS, and the samples were processed on the ‘Nucleic Acid PrepSta-
tion’ using the ‘Applied Biosystems Total RNA Chemistry’ according
to the manufacturer’s instructions. The puriﬁed RNA was eluted in a
total volume of 150 lL. The integrity of total RNA was checked on
an Agilent 2100 Bioanalyser using the RNA 6000 Nano LabChip kit
(Agilent Technologies, Palo Alto, CA).
2.4. Reverse transcription and TaqMan polymerase chain reaction
Two hundred nanograms of total RNA (10 lL) were reverse-tran-
scribed into cDNA using the high-capacity cDNA Archive Kit with
random hexamers according to the supplier’s instructions. The repor-
ter for the TaqMan probes, all purchased from Applied Biosystems,
was FAM. A TaqMan Universal PCR Master Mix was mixed with
the designed assays as follows: 12.5 lL of 2· Master mix, 0.62 lL of
the cDNA solution and 1.875 lL of water. The temperature program
was 50 C for 2 min, 95 C for 10 min, 95 C for 9 s and then 60 C
for 1 min for 40 cycles. Data were normalised to glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) signal.
2.5. Microsome preparation
Once the cells had been washed with PBS, each dish was scratched in
1 mL of 50 mM phosphate buﬀer, pH 7.4, containing 0.25 M saccha-
rose, 10 mM EDTA and 0.1 mM dithiothreitol (DTT). The cells were
grinded in a glass potter in ice and sonicated for 10 s. Then, the mix
was centrifuged at 10000 · g for 20 min at 4 C; the supernatant was
collected and centrifuged at 105000 · g for 60 min at 4 C. The pellet
was washed in 0.5 mL of 100 mM phosphate buﬀer, pH 7.4, containing10 mM EDTA and 0.1 mM DTT. The microsomal subcellular fraction
was stored until use at 80 C in 0.4 mL of 100 mM phosphate buﬀer,
pH 7.4, containing 1 mM EDTA, 20 mM DTT and 20% glycerol (v/v).
Microsomal protein content was determined using the Bio-Rad protein
assay based on the Bradford dye-binding procedure with bovine serum
albumin as standard.
2.6. Assay of monooxygenase enzymatic activities
The x and (x  1)-hydroxylations of lauric acid were determined by
HPLC as previously reported in microsomes from rat- and human-
liver [24,25] using lauric acid (0.1 mM; speciﬁc activity 74 kBq/mL)
as substrate.
2.7. RP-HPLC analysis
The x and (x  1)-hydroxylated metabolites of lauric acid and
residual substrate were separated by RP-HPLC using a 5-lm Ultra-
sphere C18 column 150 · 4.6 mm (Beckman, France) as previously de-
scribed [24,28]. The HPLC chromatography apparatus was equipped
with a Flo-One Beta radiometric detector (Packard, Meriden, CT).
Metabolic rates were calculated from the percent-transformed areas
of metabolites and expressed in pmol min1 mg1 of protein.
2.8. Immunoquantiﬁcation of CYP4A11 protein
Aliquots of cell microsomal preparations (100 lg) were separated by
electrophoresis on 9% SDS–polyacrylamide gels and then electropho-
retically transferred to nitrocellulose sheets. These sheets were blocked
with TBS containing 5% (w/v) BSA and 0.1% (v/v) Tween 20 for 1 h at
room temperature before overnight incubation, at 4 C, with rabbit
anti-CYP4A11 primary polyclonal antibody. After washing with
TBS/tween, they were treated with TBS containing anti-rabbit Ig-bio-
tinylated species-speciﬁc secondary antibody conjugated to streptavi-
dine-horseradish peroxidase and then washed with TBS/tween. The
peroxidase activities were evidenced by ECL detection using luminol.
Quantiﬁcation of the blots was performed by image processing scan
analysis (Gel Doc XR, Biorad, France); the integrated peaks were
expressed as arbitrary units relative to protein quantity.
Relative amounts of protein loaded and transferred onto the blot
were assessed by Coomassie blue staining and quantiﬁed by image pro-
cessing scan analysis (Gel Doc XR); the coloration of each lane varied
no more than 5%.
2.9. Statistical analysis
The results are expressed as means ± S.D. The diﬀerences between
control and treatment groups were assessed by analysis of variance fol-
lowed with Student’s t tests and considered as statistically signiﬁcant
when P was <0.05.3. Results
3.1. Dose- and time-dependent decrease of CYP4A11 mRNA
level by ATRA
In order to study the eﬀect of ATRA on CYP4A11 gene reg-
ulation, fully diﬀerentiated HepaRG cells were incubated with
increasing concentrations of ATRA in the medium. Unexpect-
edly, CYP4A11 mRNA was quickly downregulated by reti-
noids (Fig. 1A); its half life was about 5 and 7 h for 1 and
10 lM ATRA, respectively. An 80% reduction was observed
for both doses after 12 h. The EC50 was 5 nM after 18 h
(Fig. 1B). These eﬀective ATRA concentrations are similar
to those reported for human plasma retinal (1.7–2 lM) [26]
and ATRA (8–16 nM) [27]. A strong downregulation of
CYP4A11 expression was also obtained in HepG2 human hep-
atoma cells 18 h after the treatment by 1 or 10 lM ATRA
(51% and 69% inhibition, respectively).
3.2. Reduction of CYP4A11 protein content by ATRA
To determine whether the decrease in CYP4A11 mRNA
level was associated with a reduction of CYP4A11 protein
Fig. 1. ATRA inhibits CYP4A11 in a time- and dose-dependent
manner. Fully diﬀerentiated HepaRG cells were incubated with 1 or
10 lM of ATRA for 6, 12, 18, 24 and 48 h in William’s E medium
supplemented with 5 U/mL penicillin, 5 lM streptomycin and 200 mM
glutamine. (A) Time-course inhibition of CYP4A11 mRNA by ATRA;
(B) dose–response regulation of CYP4A11 mRNA by ATRA.
CYP4A11 mRNA levels were determined by real-time RT-PCR. Data
were normalised to GAPDH signal and expressed as means ± S.E.M.
(n = 4) of vehicle control in percent. **P < 0.01.
Fig. 2. Eﬀect of ATRA treatment on the expression of CYP4A11
protein in HepaRG microsomes. Immunoblot analysis of CYP4A11
content in microsomes (100 lg of protein per lane) from fully
diﬀerentiated HepaRG cells (control) or treated for 24 h with 5 lM
ATRA or 1 lM LTB4. Data shown is representative of three
independent experiments with identical results.
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anti-CYP4A11 antibody (Fig. 2). A 4-fold decrease of
CYP4A11 protein was observed following treatment of He-
paRG with 5 lM ATRA for 24 h. As a control, no change
was observed by treatment with 1 lM leukotriene B4 (LTB4)
for 24 h.
3.3. Inhibition of laurate hydroxylation by ATRA
Lauric acid, a major CYP4A11 substrate [2], was incubated
with microsomes from HepaRG cells treated or not with 5 lM
ATRA (Fig. 3). In agreement with literature data [25,28],
(x  1)- and x-hydroxylated lauric acid were generated byFig. 3. ATRA inhibits laurate hydroxylation. RP-HPLC proﬁles of metabol
cells: (A) untreated; (B) treated with 5 lM ATRA; (C) treated with 1 lM LT
lauric acid, respectively. Data shown is representative of two independent excontrol microsomes at the ratio of 1/7. The NADPH-depen-
dent formation of 11- and 12-hydroxylated laurate was
0.07 ± 0.03 and 0.51 ± 0.08 nmol/min/mg protein, respectively.
The requirement of molecular oxygen and NADPH as sources
of electrons (data not shown) for the production of both
metabolites suggests the involvement of a CYP enzyme.
The treatment of HepaRG cells with 5 lM ATRA caused a
56% reduction of the microsomal lauric acid x-hydroxylase
(x-LAH) activity (metabolic rate of 0.29 nmol/min/mg
protein), but had no eﬀect on the formation of the (x  1)-
hydroxylated metabolite. Laurate hydroxylation was unaf-
fected by incubating laurate and ATRA at equimolar
concentration, with recombinant CYP4A11 (data not shown);
this experiment ruled out a possible competition between lau-
rate and ATRA for oxidation. Treatment of the cells with
1 lM LTB4 induced no signiﬁcant change in x-LAH activity.
Moreover, the microsomal metabolism of nifedipine, a
CYP3A4 substrate [29], remained unchanged after cell
treatment by ATRA.
3.4. De novo protein synthesis is not required for CY4A11
suppression by ATRA
In order to determine whether the eﬀect of ATRA was asso-
ciated with de novo protein synthesis, HepaRG cells were
pre-incubated for 30 min with cycloheximide, an inhibitor of
protein synthesis; then 1 lM ATRA was added or not to the
culture medium for 24 h. As shown in Table 1 no signiﬁcant
change in CYP4A11 gene expression was detected uponites generated from 0.1 mM lauric acid by microsomes from Hepa RG
B4. Peaks 1 and 2 were characterised as (x  1)- and x-hydroxylated
periments with identical results.
Table 1
Eﬀect of cycloheximide on ATRA-induced decrease in CYP4A11
mRNA
CTL ATRA Cyclo Cyclo + ATRA
CYP4A11 1 0.165 ± 0.08 0.71 ± 0.14 0.027 ± 0.02
FAS 1 2.46 ± 0.26 0.55 ± 0.01 0.75 ± 0.24
Fully diﬀerentiated HepaRG cells were pre-incubated, or not, for
30 min with 10 lM cyclo and then treated or not with 1 lMATRA for
24 h. CYP4A11 and FAS expression of mRNA level were determined
by real-time RT-PCR. Data were normalised to GAPDH signal and
expressed as means ± S.E.M. (n = 4) of vehicle control in percent.
Fig. 4. Half-life analysis of mRNA CYP4A11. Fully diﬀerentiated
HepaRG cells were pre-treated with 1 lM ATRA during 2 h then
treated with 80 lM of a transcription inhibitor: DRB over various
periods of time (0, 2, 4, 6, 8 and 20 h) in William’s E medium
supplemented with 5 U/mL penicillin, 5 lM streptomycin and 200 mM
glutamine. CYP4A11 mRNA levels were performed by real-time RT-
PCR analysis as described using the TaqMan chemistry. mRNA level
at all times is expressed as percentage of the control of each time.
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downregulation of CYP4A11 gene expression in cyclohexi-
mide-treated cells. As a control, we analysed FAS gene expres-
sion known to be inducible by ATRA [14]. No increase of FAS
mRNA was observed after treatment by cycloheximide, as ex-
pected, which shows that cycloheximide was indeed active.
Therefore, protein neosynthesis is not required for the inhibi-
tion of CYP4A11 gene expression by ATRA, which is in
favour of a direct inhibitory mechanism.
3.5. ATRA does not aﬀect CYP4A11 mRNA half-life
The reduced level of CYP4A11 mRNA may result from
either a decrease in transcription or an enhanced RNA degra-
dation. We thus examined the eﬀect of ATRA on CYP4A11
mRNA stability by incubating or not, for 2 h, cells with ATRA
and then with 80 lM 5,6-dichloro-1-b-ribofuranosyl benzami-
dazole (DRB), a classical inhibitor of RNA synthesis. After
transcription inhibition, no signiﬁcant change in the CYP4A11
half-life was induced by incubation with 1 lM ATRA (Fig. 4);
this result suggests that regulation of CYP4A11 gene expres-
sion by ATRA occurs mainly at the transcriptional level.
3.6. ATRA and PPARa ligands trigger opposite eﬀects on
CYP4A11 gene expression in HepaRG human hepatoma
cells
Retinoid eﬀects are mediated by RAR and RXR nuclear
receptors. To gain some insight into the molecular mechanism
of ATRA inhibition, we assessed not only its eﬀect, but also
that of 9-cis-RA another retinoid receptor ligand, on CYP4A11Fig. 5. Eﬀect of retinoids and PPAR ligands on CYP4A11 and FAS genes ex
ATRA, 1 lM 9-cis-RA, 100 lM Bezaf, 1 lM LTB4, 25 lM 2BrP or 1 lM PG
time RT-PCR. Data were normalised to GAPDH signal and expressed as mea
ND: not determined.gene regulation. A major diﬀerence between ATRA and 9-cis-
RA is that the latter can bind to both RAR and RXR whereas
the former binds only to RAR [30]. Fig. 5 highlights a signiﬁ-
cant inhibition of CYP4A11 gene expression by both com-
pounds in HepaRG cells. These data indicate that the
primary eﬀect of ATRA on CYP4A11 gene repression is med-
iated by RAR, rather than RXR. The high aﬃnity of retinoids
for PPARb and their ability to mediate transcription [31] also
led us to investigate the eﬀect of L-165,041, a PPARb selective
agonist, on CYP4A11 gene expression. First, we analysed the
PPAR receptors levels. Real-time reverse transcription (RT)-
PCR experiments were performed using 200 ng of total mRNA:
for PPARa, Ct = 25.8 ± 0.35, for PPARb, Ct = 24.3 ± 0.14, for
PPARc, Ct = 23.4 ± 0.25. As a comparison, Cts for GAPDH
was 17.0 ± 0,05, for CYP4A11, Ct = 24.6 ± 0.4 and for FAS
Ct = 22.6 ± 0.11. Therefore all PPAR isoforms are expressed
in fully diﬀerentiated HepaRG cells.pression. Fully diﬀerentiated HepaRG cells were incubated with 1 lM
J2 for 18 h. CYP4A11 and FAS mRNA levels were performed by real-
ns ± S.E.M. (n = 4) of vehicle control in percent. *P < 0.05; **P < 0.01.
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pression. A PPARb dependent CYP4A11 inhibition by ATRA
is, thus, unlikely. Fig. 5 also shows a signiﬁcant increase of
CYP4A11 gene expression by an 18-h treatment of HepaRG
cells with PPARa activators, i.e., bezaﬁbrate (Bezaf), 2-bromo-
palmitate (2BrP), an un-metabolisable fatty acid derivative, or,
although not reaching signiﬁcance, LTB4. One should note the
inhibition of CYP4A11 gene expression by 15-deoxy-D12,14-
prostaglandin J2 (PGJ2), a PPARc selective ligand. The con-
comitant treatment with ATRA and the strong inducer of
CYP4A11, bezaﬁbrate, led to a weak inhibition of CYP4A11
gene expression, suggesting that Bezaf activation of CYP4A11
is less eﬃcient that ATRA-induced inhibition. As expected
from [14], FAS gene expression was upregulated by retinoids
in these cells.4. Discussion
Our investigations of CYP4A11 gene regulation in the well-
diﬀerentiated HepaRG human hepatoma cell line highlight a
retinoid-dependent repression of the gene expression. We also
show an opposite eﬀect of bezaﬁbrate and retinoids on fatty
acid hydroxylation. Since CYP4A11 is the main x-LAH in li-
ver, this duality of eﬀects is likely involved in control of lipid
levels in human liver. Its role is still poorly understood since,
in humans, it metabolises endogenous substrates such as med-
ium- or long-chain fatty acids, but not arachidonic acid [32].
Instead of acting through catabolic processes, CYP4A11 could
generate the medium- and long-chain x-hydroxylated fatty
acids endowed with various biological properties.
Retinoic acid has been shown to regulate genes involved in
fatty acid- and cholesterol-metabolism [33]. The above-de-
scribed inhibition of CYP4A11 gene expression and activity
in response to retinoids led us to hypothesise that retinoids
may generate an adaptation of fatty acid metabolism by sup-
pressing fatty acid oxidation and by inducing fatty acid synthe-
sis via control of the FAS gene.
ATRA and 9-cis-RA are important regulators of gene
expression. Among the 3 types of nuclear receptors, RAR,
RXR or PPARb, known to be activated by retinoids, our
investigations indicate that the main receptor involved in
CP4A11 downregulation in human hepatocyte like cells is
RAR.
ATRA usually aﬀects gene transcription by binding to the
nuclear RAR receptor, which functions as a ligand-activated
transcription factor binding to speciﬁc DNA sequences, the
RAREs (retinoic acid response elements), thereby regulating
the RA-responsive genes. A computer search within the 2500
bp immediately upstream the translation initiation site of
CYP4A11 (MatInspector, http://www.genomatix.de/) revealed
the presence of numerous putative regulatory elements, but no
consensus RAREs. This observation suggests that a RARE
element may lie elsewhere along the gene or RA action requires
a sequence distinct from RARE. Besides this classical way of
action, RARs also aﬀect gene expression by interacting with
other transcription factors such as AP-1 and GATA-2, thereby
regulating gene transcription through other sequence motifs
[34,35]. One possibility might be that RAR represses
CYP4A11 transcription by physically sequestering RXR or
other essential coactivators or partners of PPAR.Modulation of gene expression by RA results primarily in
the induction of genes but also, in some cases, in their repres-
sion. In most RA-dependent repressive eﬀects, RA has been
shown to prevent the increase of transcription more than to
repress basal gene expression [36–38]. The mechanism
through which ATRA antagonizes activation of gene tran-
scription involves repression of the transcriptional activity
of nuclear factors such as Nuclear Factor of Activated T-cell
[38], AP-1 [37,39] or Oct4 (A) and may implicate titration of
shared associated proteins or coactivators [37], dephosphoryl-
ation of a transcription factor [39] or competition for DNA
binding sites [38]. In only a few of reports, RA has been
shown to downregulate basal gene expression, i.e., aldehyde
dehydrogenase 1 [40], or a-fetoprotein [41]. These repressive
eﬀects are mediated by transcription factors, i.e., CAAT/en-
hancer-binding protein b [40] or hepatocyte nuclear factor 1
and 4 [41,42].
Since ATRA induces growth arrest in rat hepatocytes and
HepG2 cells, together with diﬀerentiation for the latter [20],
we wondered whether the inhibitory eﬀect of ATRA on
CYP4A11 would result from HepaRG diﬀerentiation by this
eﬀector. This hypothesis is unlikely for several reasons. First,
ATRA treated cells were already fully diﬀerentiated under
our experimental conditions [23], and the rapid eﬀect of ATRA
occurred in a shorter time scale than the diﬀerentiation pro-
cess. Second, CYP4A11 gene expression was in fact increased
as the diﬀerentiation process proceeded (not shown).
Fatty acid metabolism is strongly implicated in carcinogen-
esis; an overexpression of CYP4A11 in human colorectal can-
cer tissue was evidenced by Microarray analysis [43]. In other
respects, ATRA can exert anti-tumoral activities and has been
used as a chemotherapeutic agent because of its strong anti-
proliferative activity against several types of cancer [17,44–46].
In the present study, we describe the ﬁrst suppressive eﬀect
of RA on an important bio-transformation function in human
liver cells.
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